These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 24811052)

  • 1. Serological studies in inflammatory bowel disease: how important are they?
    Papp M; Lakatos PL
    Curr Opin Gastroenterol; 2014 Jul; 30(4):359-64. PubMed ID: 24811052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic Autoantibodies Against CUZD1 and GP2 Are Associated with Distinct Clinical Phenotypes of Crohn's Disease.
    Michaels MA; Jendrek ST; Korf T; Nitzsche T; Teegen B; Komorowski L; Derer S; Schröder T; Baer F; Lehnert H; Büning J; Fellerman K; Sina C
    Inflamm Bowel Dis; 2015 Dec; 21(12):2864-72. PubMed ID: 26273818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1].
    Papp M; Sipeki N; Tornai T; Altorjay I; Norman GL; Shums Z; Roggenbuck D; Fechner K; Stöcker W; Antal-Szalmas P; Veres G; Lakatos PL
    J Crohns Colitis; 2015 Aug; 9(8):659-68. PubMed ID: 25968583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens: the glycoproteins CUZD1 and GP2.
    Komorowski L; Teegen B; Probst C; Aulinger-Stöcker K; Sina C; Fellermann K; Stöcker W
    J Crohns Colitis; 2013 Nov; 7(10):780-90. PubMed ID: 23140841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies Against Glycoprotein 2 Isoforms in Pediatric Patients with Inflammatory Bowel Disease.
    Röber N; Noß L; Goihl A; Reinhold D; Jahn J; de Laffolie J; Johannes W; Flemming GM; Roggenbuck D; Conrad K; Laass MW
    Inflamm Bowel Dis; 2017 Sep; 23(9):1624-1636. PubMed ID: 28691939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease.
    Roggenbuck D; Hausdorf G; Martinez-Gamboa L; Reinhold D; Büttner T; Jungblut PR; Porstmann T; Laass MW; Henker J; Büning C; Feist E; Conrad K
    Gut; 2009 Dec; 58(12):1620-8. PubMed ID: 19549613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies.
    Bogdanos DP; Rigopoulou EI; Smyk DS; Roggenbuck D; Reinhold D; Forbes A; Laass MW; Conrad K
    Autoimmun Rev; 2011 Dec; 11(2):143-8. PubMed ID: 21983481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort.
    Papp M; Altorjay I; Dotan N; Palatka K; Foldi I; Tumpek J; Sipka S; Udvardy M; Dinya T; Lakatos L; Kovacs A; Molnar T; Tulassay Z; Miheller P; Norman GL; Szamosi T; Papp J; ; Lakatos PL
    Am J Gastroenterol; 2008 Mar; 103(3):665-81. PubMed ID: 18047543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmunity in Crohn's Disease-A Putative Stratification Factor of the Clinical Phenotype.
    Roggenbuck D; Reinhold D; Baumgart DC; Schierack P; Conrad K; Laass MW
    Adv Clin Chem; 2016; 77():77-101. PubMed ID: 27717419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies.
    Pavlidis P; Komorowski L; Teegen B; Liaskos C; Koutsoumpas AL; Smyk DS; Perricone C; Mytilinaiou MG; Stocker W; Forbes A; Bogdanos DP
    Clin Chem Lab Med; 2016 Feb; 54(2):249-56. PubMed ID: 26351932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease.
    Roggenbuck D; Reinhold D; Wex T; Goihl A; von Arnim U; Malfertheiner P; Büttner T; Porstmann T; Porstmann S; Liedvogel B; Bogdanos DP; Laass MW; Conrad K
    Clin Chim Acta; 2011 Apr; 412(9-10):718-24. PubMed ID: 21195704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticarbohydrate antibodies as markers of inflammatory bowel disease in a Central European cohort.
    Malickova K; Lakatos PL; Bortlik M; Komarek V; Janatkova I; Lukas M
    Eur J Gastroenterol Hepatol; 2010 Feb; 22(2):144-50. PubMed ID: 19927001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody markers in the diagnosis of inflammatory bowel disease.
    Mitsuyama K; Niwa M; Takedatsu H; Yamasaki H; Kuwaki K; Yoshioka S; Yamauchi R; Fukunaga S; Torimura T
    World J Gastroenterol; 2016 Jan; 22(3):1304-10. PubMed ID: 26811667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crohn's disease specific pancreatic antibodies: clinical and pathophysiological challenges.
    Roggenbuck D; Reinhold D; Schierack P; Bogdanos DP; Conrad K; Laass MW
    Clin Chem Lab Med; 2014 Apr; 52(4):483-94. PubMed ID: 24231127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features.
    Annese V; Piepoli A; Perri F; Lombardi G; Latiano A; Napolitano G; Corritore G; Vandewalle P; Poulain D; Colombel JF; Andriulli A
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1143-52. PubMed ID: 15569117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of tolerance to one or two major targets in Crohn's disease or just cross-reactivity?
    Roggenbuck D; Bogdanos D; Conrad K
    J Crohns Colitis; 2013 Aug; 7(7):e273-4. PubMed ID: 23337370
    [No Abstract]   [Full Text] [Related]  

  • 17. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease.
    Peeters M; Joossens S; Vermeire S; Vlietinck R; Bossuyt X; Rutgeerts P
    Am J Gastroenterol; 2001 Mar; 96(3):730-4. PubMed ID: 11280542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour.
    Ferrante M; Henckaerts L; Joossens M; Pierik M; Joossens S; Dotan N; Norman GL; Altstock RT; Van Steen K; Rutgeerts P; Van Assche G; Vermeire S
    Gut; 2007 Oct; 56(10):1394-403. PubMed ID: 17456509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases.
    Farkona S; Soosaipillai A; Filippou P; Liaskos C; Bogdanos DP; Diamandis EP; Blasutig IM
    Clin Chem Lab Med; 2017 Aug; 55(10):1574-1581. PubMed ID: 28343172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic autoantibodies and autoantibodies against goblet cells in pediatric patients with inflammatory bowel disease.
    Kovacs M; Lakatos PL; Papp M; Jacobsen S; Nemes E; Polgar M; Solyom E; Bodi P; Horvath A; Muller KE; Molnar K; Szabo D; Cseh A; Dezsofi A; Arato A; Veres G
    J Pediatr Gastroenterol Nutr; 2012 Oct; 55(4):429-35. PubMed ID: 22465933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.